Bleichmar Fonti & Auld LLP is investigating The Ensign Group, Inc. for potential securities fraud following two stock declines. The investigation concerns whether Ensign misled investors about care quality at its nursing facilities, as well as its growth, margins, and regulatory compliance. On June 8, 2026, Hunterbrook Capital published a report alleging that Ensign understaffed facilities and routed government payments to affiliates, causing an 8.2% stock drop from $170.30 to $156.42 per share. On June 11, 2026, Muddy Waters Research alleged that Ensign used off-site administrators to feign regulatory compliance at an estimated 20% of facilities, leading to a further 3% decline from $151.65 to $147.13 per share. Investors are encouraged to contact the firm, which represents clients on a contingency fee basis.
The Ensign Group IncInvestigation for securities fraud and allegations of understaffing and regulatory non-compliance at nursing facilities.